iBio Inc（IBIO）の株式分析IBIOiBio Inc

iBio, Inc. is a biotech company leveraging artificial intelligence and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. It has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, iBio Inc. is not a strong buy due to its recent performance and financial losses. The stock is trading at $1.36, which is significantly lower than the analyst price target of $7, indicating potential upside. However, the RSI is at 30.888, suggesting it is oversold, and the company has a gross margin of 100%, which is excellent. The main risk is the ongoing net losses, which reached -$7.73 million in Q3 2026, indicating continued financial struggles.